|Bid||60.71 x 100|
|Ask||61.46 x 200|
|Day's Range||60.62 - 62.12|
|52 Week Range||53.63 - 66.80|
|PE Ratio (TTM)||59.18|
|Forward Dividend & Yield||1.92 (3.10%)|
|1y Target Est||N/A|
In 2018, the biotech industry is expected to witness a continuation of last year’s favorable trends. Noteworthy among them was the approval of Novartis’ (NYSE:NVS) Kymriah, the first cell-based gene therapy known as CAR-T therapy, which is an innovative treatment option for cancer. Spark Therapeutics’s Luxturna, the first gene therapy to treat a rare, inherited form of childhood blindness, was also approved last year.
While Merck & Co., Inc. (NYSE:MRK) had gotten off to a modest pace to start the year, the last few trading sessions have been rather explosive. Specifically, on Jan. 16, MRK stock rocketed higher by about 6%. All told, Merck stock is up more than 10% this year.
What Could Drive Bristol-Myers Squibb in 2018? In December 2017, the U.S. FDA (Food and Drug Administration) approved Bristol-Myers Squibb’s (BMY) Opdivo as adjuvant therapy for individuals with melanoma with the involvement of lymph nodes or metastatic disease who have undergone complete resection. The objective of the adjuvant therapy is to reduce the risk of recurrence after surgical removal of the tumor.
Smoking, which causes many lung cancer cases, has made advanced lung cancer a big market for pharmaceutical companies, and the competition has been fierce.
Merck's (MRK) Keytruda in combination with Eli Lilly's Alimta and carboplatin meet dual primary endpoints in a confirmatory phase III study for the first-line treatment of lung cancer.
On a day stocks bounced up and down, shares of Energizer Holdings rose on acquisition news, and Merck reported positive results in a lung cancer trial.
A strong open for the stock market Tuesday saw the Dow Jones industrial average cross the 26,000 level early, but gains faded badly by the close.
The Dow Jones Industrial Average broke through 26,000 on Tuesday, but ended the day with a small loss. The S&P 500 and Nasdaq also finished lower.
Merck & Co., Inc. (NYSE:MRK) shares were soaring on Tuesday following the company’s release of its latest lung cancer treatment results. The company rolled out a combination of immunotherapy Keytruda and two chemotherapy medications, which helped lung cancer patients live longer and stopped the illness from advancing, according to early results from a study. The results will be unveiled at an upcoming medical meeting, although the date and location of the meeting are unknown.
Merck said a Phase 3 study of its immuno-oncology drug Keytruda in tandem with chemotherapy drugs pemetrexed (Alimta) and cisplatin or carboplatin was successful.
Merck & Co., Inc. (NYSE: MRK ) announced encouraging data Tuesday from a key study of patients with lung cancer. The combination of Merck's blockbuster drug Keytruda and two chemotherapy medicines helped ...
Positive lung cancer results for Merck & Co Inc's blockbuster drug Keytruda assuaged investor concerns about delays in testing and the withdrawal of an application for European use of the drug, sending the drugmaker's shares up more than 6 percent. A cocktail of immunotherapy Keytruda and two chemotherapy medicines helped lung cancer patients live longer and stopped the disease from advancing, early results from a study showed, Merck said.
Merck & Co. Inc. shares jumped almost 7% Tuesday, after the company announced positive results in a late-stage lung cancer trial. The New Jersey-based drug company said the Phase 3 trial of Keytruda in ...
Can Teva Pharmaceutical's Restructuring Plan Help It Recuperate? In December 2017, Teva Pharmaceutical Industries (TEVA) laid out a detailed restructuring plan for the company to turn around its ailing business due to a number of challenges it’s facing.
Among the companies with shares expected to trade actively in Monday's session are Citigroup Inc., General Electric Co., UnitedHealth Group Inc., Apple Inc., Alphabet Inc. and Amazon.com Inc.
Merck & Co Inc said on Tuesday that a key late-stage study testing its blockbuster drug Keytruda as a treatment for a type of lung cancer was successful. The trial, which tested Keytruda as a first line ...
AstraZeneca (AZN) and Merck (MRK) announce approval of label expansion of ovarian cancer drug, Lynparza, to include HER2-/HR+ breast cancer with germline BRCA-mutation.